Navigation Links
Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
Date:2/13/2008

FRAZER, Pa., Feb. 13 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) issued the following statement in response to a complaint filed today by the U.S. Federal Trade Commission (FTC) in U.S. District Court for the District of Columbia challenging the validity of certain agreements entered into by the company in late 2005 and early 2006 to settle the PROVIGIL(R) (modafinil) [C-IV] patent infringement litigation and seeking to permanently enjoin the Company from maintaining or enforcing these agreements.

Cephalon stands by the strength and validity of our PROVIGIL patents and the legal basis for these settlements. We are disappointed that the FTC has determined to challenge these agreements as we believe they fully comply with both the spirit and letter of the antitrust laws. As importantly, our settlements confer a meaningful benefit to U.S. consumers by providing for the entry of generic modafinil three years early.

Cephalon is prepared to vigorously defend itself in this matter and expects to prevail.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL, FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone fo
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
2. Cephalon General Counsel John E. Osborn to Resign Position
3. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
4. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
5. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Announces Strong Third Quarter Financial Results
9. Cephalon Quarterly Conference Call Invitation
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... commercializes proprietary technologies and products for advanced microarray diagnostics, ... fiscal first quarter ended December  31, 2014. All figures ... unless otherwise stated. "During the quarter ... existing customers and add to our sales pipeline," said ...
(Date:2/26/2015)... 2015   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... Chief Executive Officer of Regulus, will present a company ... Annual Healthcare Conference on Wednesday, March 4, 2015 at ... the Boston Marriott Copley Place.  The ...
(Date:2/26/2015)... FT. LAUDERDALE, Fla. , Feb. 26, 2015 /PRNewswire/ ... discussed growth priorities driven by key research advancements ... Health segments at today,s Bank of America Merrill Lynch ... worldwide met the challenge of building grain supplies the ... expected to continue at the pace of the last ...
(Date:2/26/2015)... February 26, 2015 On behalf of ... affiliated companies, Wilentz, Goldman & Spitzer, P.A. ... secrets lawsuit against Genewiz Inc. in excess of $10 ... utilized GenScript’s trade secrets, and that it improperly hired ... entered an order denying motions for judgment notwithstanding the ...
Breaking Biology Technology:SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... Thailand, Sept. 8 Don Margolis, Chairman of,The ... ) based in,Bangkok, Thailand told The Wall Street ... that future profits inside the stem cell,research sector ... next five years, even for,companies specializing in Repair ...
... PRINCETON, New Jersey and SAN DIEGO,California, September 8 , ... for Continuous Process,Chemistry Technologies and for Further Global Expansion, ... investment of $3.3M,by a group of private and financial ... Graphisoft and Dave Tapolczay, CEO of Medical,Research Council Technology ...
... Sept. 8 /PRNewswire-FirstCall/,-- Concuity, a healthcare division ... a leading,provider of contract management and revenue ... today announced that Valley Baptist Health,System has ... more,accurately calculate payments from managed care and ...
Cached Biology Technology:Stem Cell Profits Five Years Away, Says Repair Stem Cell Institute Chairman to The Wall Street Transcript 2World Leader in Bench-Top Flow Chemistry Instruments ThalesNano, Inc. Closes Funding Round 2Valley Baptist Health System Selects Concuity's ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 2Valley Baptist Health System Selects Concuity's ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 3Valley Baptist Health System Selects Concuity's ClearContracts to More Accurately Calculate Payments from Managed Care and Government Payers 4
(Date:2/12/2015)... Minn. , Feb. 12, 2015   ... company specializing in clinical study management systems, has ... Program , further distinguishing iMedNet ... Clinical Research Organizations (CROs) and healthcare consultants.  Building ... support, prospective customer referrals and numerous co-marketing opportunities), ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
(Date:2/5/2015)... Conn. , Jan. 26, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... new corporate website ( http://www.nxt-id.com/ ) as part of ... smart wallet. The Company launched its new consumer website ... Gino Pereira , CEO of NXT-ID said, "Our new ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... companies could economically convert their operations to wood boilers ... forestry researchers. The conversion to wood-powered burners would make ... in areas that have access to large timber resources ... professor of wood operations, Penn State. Wood is ...
... University biology professor Chris Martine has discovered and described ... City. Martine, who named the plant Solanum cowiei , ... . Martine described the plant as "gender bending," ... by producing pollen. "What they,re really doing is ...
... Professor Keon Jae Lee and Professor ... Science and Engineering at KAIST has developed the biotemplated ... Nature has its own capabilities to spontaneously ... as shells, sea sponges, and bone minerals. For instance, ...
Cached Biology News:Companies could make the switch to wood power 2Unlikely collaboration leads to discovery of 'gender-bending' plant 2Unlikely collaboration leads to discovery of 'gender-bending' plant 3
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
... A.D. Smith et.al. (1997) ... entries on current biochemistry & ... than 17,000 headwords. Entries give ... the processes in which they ...
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
The Protein Kinase Factsbooks (2 Volume Set)...
Biology Products: